Do you think that the acquisition between GSK and Domantis LTD has affected GSK financially in any way?
The question might be rephrased from 'has affected' to 'will affect', and yes, it undoubtedly will. Based on some further research (attached), it appears the company is making a shift in their approach to research and development. Big pharma must spend significant amounts to keep the pipeline of drugs flowing, and the US has been a leader in R&D in the past. For GSK to continue to compete in the world market for pharma, they must ramp up ...
The solution includes research about the acquisition plus an opinion of the effects of the acquisition in terms of world leadership in several areas of big pharma.